<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02156336</url>
  </required_header>
  <id_info>
    <org_study_id>HIPG-CLIN-2014-01</org_study_id>
    <nct_id>NCT02156336</nct_id>
  </id_info>
  <brief_title>Ranolazine for Diabetic Peripheral Neuropathic Pain (DPNP)</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Randomized, Parallel Assignment, U.S. Study of Ranolazine for the Treatment of Patients With Diabetic Peripheral Neuropathic Pain (DPNP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Horizons International Peripheral Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Horizons International Peripheral Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine if patients suffering from diabetic peripheral&#xD;
      neuropathic pain treated with ranolazine will have a greater reduction in pain compared to&#xD;
      placebo.&#xD;
&#xD;
      Hypothesis: From the prior clinical observations, and analgesic efficacy in the preclinical&#xD;
      animal model of neuropathic pain, the investigators hypothesize that subjects randomized to&#xD;
      ranolazine will show a greater reduction in diabetic neuropathic pain compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Not enough patients met study criteria for enrollment.&#xD;
  </why_stopped>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">February 8, 2017</completion_date>
  <primary_completion_date type="Actual">February 8, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fifty percent or greater reduction in the mean Numeric Rating Scale (11-point NRS 0-10) recorded in the subjects' diaries from ranolazine compared to placebo.</measure>
    <time_frame>6 weeks (42 Days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life Assessment as measured by SF-36 v2</measure>
    <time_frame>Randomization (Day 0) and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain assessment measured by the Visual Analog Scale</measure>
    <time_frame>Randomization (Day 0), Day 14, Day 28, Day 42, and Day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain assessment measured by Short-Form McGill Pain Questionnaire</measure>
    <time_frame>Randomization (Day 0) and Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain of patients with arterial ischemia measured by Short-Form McGill Pain Questionnaire</measure>
    <time_frame>Randomization (Day 0), Day 14, Day 28, Day 42, and Day 56</time_frame>
    <description>Pain reduction of ranolazine versus placebo in subjects with diabetic peripheral neuropathic pain (DPNP) and arterial ischemia compared to those with DPNP without arterial ischemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional pain medication</measure>
    <time_frame>Randomization (Day 0), Day 14, Day 28, Day 42, and Day 56</time_frame>
    <description>Additional pain medication after the baseline visit as needed for pain reduction in addition to the study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Adverse Events after randomization</measure>
    <time_frame>56 Days</time_frame>
    <description>The rates and severity of Adverse Events (AEs) from Randomization (Day 0) through Termination (Day 56)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Serious Adverse Events after randomization</measure>
    <time_frame>56 Days</time_frame>
    <description>A serious adverse event (SAE), also may be called a serious adverse drug reaction, is any untoward medical occurrence that at any dose:&#xD;
results in death,&#xD;
is life-threatening,&#xD;
requires inpatient hospitalization or prolongation of existing hospitalization,&#xD;
results in persistent or significant disability/incapacity, or&#xD;
is a congenital anomaly/birth defect.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Diabetic Peripheral Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>500 mg PLACEBO PO 2 times a day for 1 week (Week 1)&#xD;
1000 mg PLACEBO PO 2 times a day for 5 weeks (Weeks 2,3,4,5,6)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RANOLAZINE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500 mg RANOLAZINE PO 2 times a day for 1 week (Week 1)&#xD;
1000 mg RANOLAZINE PO 2 times a day for 5 weeks (Weeks 2,3,4,5,6)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranolazine</intervention_name>
    <description>Oral administration, BID; for a maximum of 51 days.</description>
    <arm_group_label>RANOLAZINE</arm_group_label>
    <other_name>Ranexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration, BID; for a maximum of 51 days.</description>
    <arm_group_label>PLACEBO</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A minimum of 18 years of age;&#xD;
&#xD;
          2. Provided signed Informed Consent Form and Health Insurance Portability and&#xD;
             Accountability Act (HIPAA) authorization for this study approved by the Institutional&#xD;
             Review Board;&#xD;
&#xD;
          3. Patients must have diabetic peripheral neuropathic pain rated at an average level of&#xD;
             six (6) or above as documented in daily diary prior to baseline visit and noted at&#xD;
             Baseline Visit;&#xD;
&#xD;
          4. Diabetic on a stable insulin regimen or oral medication regimen as determined by the&#xD;
             investigator [It is recommended Hba1c &lt; 9.5%, making a note that lab normal values may&#xD;
             vary among sites.];&#xD;
&#xD;
          5. Clinical Exam Results:&#xD;
&#xD;
               1. 5.07 Semmes-Weinstein Monofilament Test Subject does not sense monofilament or&#xD;
                  evokes an abnormal response in a minimum of two (2) out of five (5) test&#xD;
                  locations on the plantar surface of the foot.&#xD;
&#xD;
               2. Pin Prick Test Subject experiences allodynia, hyperalgesia, or sensory loss in&#xD;
                  two (2) out of five (5) test locations in the plantar surface - four (4) and&#xD;
                  dorsum - one (1) of the foot.&#xD;
&#xD;
          6. Willing and able to comply with the requirements of the protocol and follow directions&#xD;
             from the clinic and research staff;&#xD;
&#xD;
          7. For female patients only:&#xD;
&#xD;
               -  Be post-menopausal (no menses for at least 2 years) or sterilized,&#xD;
&#xD;
               -  If subject of childbearing potential, not breastfeeding, has a negative pregnancy&#xD;
                  test at Baseline (pre-randomization, Day 0), has no intention of becoming&#xD;
                  pregnant during the course of the study, and is using one or more of the&#xD;
                  following contraceptive measures:&#xD;
&#xD;
                    1. Stable regimen of hormonal contraception&#xD;
&#xD;
                    2. Intra-uterine device&#xD;
&#xD;
                    3. Condoms with spermicide&#xD;
&#xD;
                    4. Diaphragm with spermicide&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of allergy or intolerance to ranolazine;&#xD;
&#xD;
          2. Any condition or concomitant medication that would preclude the safe use of ranolazine&#xD;
             as outlined in the prescribing information sheet;&#xD;
&#xD;
          3. In the judgment of the investigator, any clinically-significant ongoing medical&#xD;
             condition that might jeopardize the patient's safety or interfere with the absorption,&#xD;
             distribution, metabolism or excretion of the study drug;&#xD;
&#xD;
          4. In the judgment of the investigator, clinically-significant abnormal physical findings&#xD;
             during screening (excluding the patient's peripheral neuropathy condition);&#xD;
&#xD;
          5. Use participation in another experimental or investigational drug or device trial;&#xD;
&#xD;
          6. Pregnant or breast feeding;&#xD;
&#xD;
          7. Cirrhosis of the liver;&#xD;
&#xD;
          8. Psychological or addictive disorders (not limited to, but including for example, drug&#xD;
             and/or alcohol dependency) that may preclude patient consent or compliance, or that&#xD;
             may confound study interpretation;&#xD;
&#xD;
          9. Taking a moderate or strong CYP3A inhibitor (e.g. diltiazem, verapamil, ketoconazole,&#xD;
             itraconazole, clarithromycin, erythromycin, nefazodone, nelfinavir, ritonavir,&#xD;
             indinavir, and saquinavir);&#xD;
&#xD;
         10. Taking inducers of Cytochrome P450, family 3, subfamily A (CYP3A) (e.g. rifampin,&#xD;
             rifabutin, rifapentine, phenobarbital, phenytoin, carbamazepine, and St. John's wort);&#xD;
&#xD;
         11. Renal impairment as defined by a calculated serum creatinine clearance of &lt; 30ml/min;&#xD;
&#xD;
         12. Lower back disorders where symptoms present similarly to DPNP;&#xD;
&#xD;
         13. Family history of long QT syndrome;&#xD;
&#xD;
         14. Congenital long QT syndrome;&#xD;
&#xD;
         15. Subjects taking tricyclic antidepressants;&#xD;
&#xD;
         16. Subjects taking anti-psychotic drugs;&#xD;
&#xD;
         17. Patient is taking &gt; 850mg metformin BID;&#xD;
&#xD;
         18. Any subjects currently taking pregabalin;&#xD;
&#xD;
         19. Any subjects currently taking gabapentin;&#xD;
&#xD;
         20. Any subject currently taking MetanxÂ®;&#xD;
&#xD;
         21. Any subjects currently taking continuous long-term narcotics;&#xD;
&#xD;
         22. Grapefruit and grapefruit containing products;&#xD;
&#xD;
         23. Use of P-gp inhibitors - cyclosporine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig M Walker, MD FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Institute of the South</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiology Associates</name>
      <address>
        <city>Fairhope</city>
        <state>Alabama</state>
        <zip>36532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute of the South</name>
      <address>
        <city>Houma</city>
        <state>Louisiana</state>
        <zip>70361</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute of the South</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gould HJ 3rd, Garrett C, Donahue RR, Paul D, Diamond I, Taylor BK. Ranolazine attenuates behavioral signs of neuropathic pain. Behav Pharmacol. 2009 Dec;20(8):755-8. doi: 10.1097/FBP.0b013e3283323c90.</citation>
    <PMID>19773645</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>May 28, 2014</study_first_submitted>
  <study_first_submitted_qc>June 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2014</study_first_posted>
  <last_update_submitted>February 9, 2017</last_update_submitted>
  <last_update_submitted_qc>February 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Peripheral Neuropathic Pain</keyword>
  <keyword>Ranexa</keyword>
  <keyword>Ranolazine</keyword>
  <keyword>Neurology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranolazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

